8. INCOME TAX (CONTINUED) (a) At 31 December 2025, all of the available losses were utilised or recognised on the balance sheet, relating to the historical and future Trofinetide royalty and milestone payments. – $2.6 million of New Zealand gross tax losses were utilised during the current financial year in relation to the 31 December 2025 tax year (2024: $23.7 million). – $34.6 million (2024: $37.2 million) of New Zealand gross tax losses carried forward, for which a Deferred Tax Asset (DTA) of $9.7 million (2024: $10.4 million) is recognised on the balance sheet. There are no New Zealand imputation credits available for use as at 31 December 2025 (2024: nil). Australian Franking credits As at 31 Dec 2025 $’000 As at 31 Dec 2024 $’000 Franking credits available at the reporting date based on a tax rate of 30% 81,823 28,021 Franking credits that will arise from the (refund)/payment of the amount of the provision for income tax at the reporting date based on a tax rate of 30% (5,778) 42,752 Franking credits available for subsequent financial years based on a tax rate of 30% 76,045 70,773 9. EARNINGS PER SHARE Basic earnings per share is calculated by dividing the profit for the period attributable to the equity holders of the company by the weighted average number of ordinary shares on issue during the period excluding shares held as treasury stock. Diluted earnings per share is calculated by dividing the profit attributable to ordinary equity holders of the company by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares. Year ended Dec 2025 $’000 Year ended Dec 2024 $’000 Profit after income tax attributable to the owners of Neuren Pharmaceuticals Limited 30,436 142,043 Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 128,241,465 127,769,432 Adjustments for calculation of diluted earnings per share: Options over ordinary shares 2,528,668 3,010,190 Weighted average number of ordinary shares used in calculating diluted earnings per share 130,770,133 130,779,622 Cents Cents Basic earnings per share 23.73 111.17 Diluted earnings per share 23.27 108.61 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS CONTINUED Neuren Pharmaceuticals Limited Annual Report 2025 45
RkJQdWJsaXNoZXIy MjE2NDg3